062 One year clinical outcomes after percutaneous coronary intervention with drug-eluting stent in patients with chronic renal failure

AimCompare the effectiveness and safety of drug-eluting stent (DES) vs bare metal stent (BMS) for percutaneous coronary intervention (PCI) in patients with chronic renal failure (CRF).Methods1126 patients treated by PCI over one year were divided in 4 patients groups, according to the type of stent used (DES vs BMS) and the creatinin clearance (CrCl). Clinical and angiographic data were prospectively entered into the web-based “Middle-Care” database. Chronic renal failure (CRF) was defined by a CrCl < 60 ml/min. The occurrence of cardiovascular (CV) death, MACCE (Death, myocardial infarction and stroke) and TLR was recorded at one year follow-up. We report the preliminary (6 months) results of patients treated between August 2007 and January 2008.Results497 patients underwent PCI: 250 (50.3%), 120 (24.1%), 81 (16.3%) and 46 (9.3%) patients were allocated in the BMS, DES, BMS CRF and DES CRF groups respectively. Mean age was 64 +/- 13 years, 82.5% were male, 24.4% had diabetes, 62.1% had an acute coronary syndrom (ACS) and 47% multivessel disease. One year follow-up was completed for 485 (97.6%) patients: 36 (7.1%) patients died, 54 (10.7%) had MACCE and 35 (6.9%) underwent TLR. The use of DES was associated with significantly less CV death and MACCE, a trend for less TLR and the same stent thrombosis (ST) rate compared with BMS use in patients with and without CRF (figure).ConclusionsThe use of DES appears to be more effective and at least as safe as BMS at one year follow up in patients with CRF. Final results will be available for the meeting